Drug
Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_4
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
NCT01937312
completedphase_4
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
NCT01937299
completedphase_4
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT01978600
Clinical Trials (3)
Showing 3 of 3 trials
NCT01937312Phase 4
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
NCT01937299Phase 4
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
NCT01978600Phase 4
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3